Cord Blood News Volume 11.45 | Nov 21 2019

TOP STORY

Hypoxia Regulates Lymphoid Development of Human Hematopoietic Progenitors

Researchers showed that hypoxia regulated cellular and metabolic profiles of umbilical cord blood-derived hematopoietic progenitor cells. Hypoxia more specifically enhanced in vitro lymphoid differentiation potentials of lymphoid-primed multipotent progenitors (LMPPs) and pro-T/natural killer cells and in vivo B cell potential of LMPPs. [Cell Rep] Full Article | Graphical Abstract

(Ranked by impact factor of the journal)

Protective Effects of Human Umbilical Cord Mesenchymal Stem Cell-Derived Conditioned Medium on Ovarian Damage

The authors showed the protective effects of human umbilical cord MSC-derived conditioned medium (hUCMSC-CM) on a cisplatin-induced ovarian injury model. hUCMSC-CM could relieve cisplatin-induced depletion of follicles and preserve fertility. [J Mol Cell Biol] Abstract

Autologous Cord Blood Cells Infusion in Preterm Neonates Safely Reduces Respiratory Support Duration and Potentially Preterm Complications

This prospective, non-randomized placebo controlled study aimed at investigating the effect of autologous cord blood mononuclear cells (ACBMNC) for preventing pre-term associated complications. Pre-term infants less than 35-weeks gestational age were assigned to receive ACBMNC intravenous or normal saline within eight hours after birth. [Stem Cells Transl Med] Full Article

Wharton’s Jelly for Augmented Cleft Palate Repair in a Rat Critical Size Alveolar Bone Defect Model

Investigators used a critical-size alveolar bone defect model in the rat to investigate the use of Wharton’s Jelly (WJ), the stem cell-rich connective tissue matrix of the umbilical cord, to generate bone within the alveolar cleft. Human WJ was isolated and implanted into a critical size alveolar bone defect model representative of secondary cleft alveolar bone grafts surgery in 10-11 week old male Sprague-dawley rats. [Tissue Eng Part A] Abstract

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: A Close-Up on Immunomodulatory Molecules Featured In Situ and In Vitro

Researchers investigated the expression of immune-related molecules, such as HLAs, IDO, CD276/B7-H3, and others, both in situ and in in vitro-cultured Wharton’s Jelly-MSCs. Morphological and biochemical techniques were used to define the expression of such molecules. They focused on the possible role of CD276/B7-H3 on T cells proliferation inhibition. [Stem Cell Rev Rep] Abstract

Human Wharton’s Jelly-Derived Mesenchymal Stem Cells Minimally Improve the Growth Kinetics and Cardiomyocyte Differentiation of Aged Murine Cardiac C-Kit Cells in In Vitro without Rejuvenating Effect

Scientists characterized cardiac c-kit cells (CCs) from aged mice and studied the effects of human Wharton’s Jelly-derived MSCs on the growth kinetics and cardiac differentiation of aged CCs in vitro. CCs were isolated from four-week- and 18-month-old C57/BL6N mice and were directly co-cultured with MSCs or separated by transwell insert. [Int J Mol Sci] Full Article

Exosomes Derived from Adipose Tissue, Bone Marrow, and Umbilical Cord Blood for Cardioprotection after Myocardial Infarction

Myocardial infarction models were established in rats, which were injected with PBS, bone marrow MSCs, adipose-derived MSCs, and umbilica cord-derived MSCs. Cardiac function was detected by ultrasonic cardiogram. [J Cell Biochem] Abstract

Identification of miRNAs from Stem Cell Derived Microparticles in Umbilical Cord Blood

Scientists detected and characterized CD34⁺ microparticles from cord blood units. Cord blood units were collected and the number of CD34⁺MPs was assessed before and after red blood cell and plasma depletion by SEPAX processing using flow cytometry analysis. [Exp Hematol] Abstract

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation

Investigators review immune reconstitution (IR), focusing on T and NK cells, and the impact of IR on clinical outcomes. Better understanding of the immune biology in umbilical cord transplantation will allow researchers to further advance this field with improved clinical practice. [J Clin Med] Full Article

Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease

The authors explore recent efforts to expand the availability of allogeneic hematopoietic stem cell transplantation, including matched unrelated, umbilical cord blood, and haploidentical stem cell sources. They consider the use of nonmyeloablative conditioning and haploidentical donor sources as emerging strategies to expand transplant availability, particularly for sickle cell disease patients with complications and comorbidities who can undergo neither matched related transplant nor myeloablative conditioning. [J Clin Med] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated with Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001^® for Severe Hemoglobinopathies

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced positive, interim data from the first two patients with severe hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 in ongoing Phase I/II clinical trials. [CRISPR Therapeutics] Press Release

Celgene Receives CHMP Positive Opinion for REVLIMID^® (Lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma

Celgene Corporation announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the approval of lenalidomide in combination with rituximab for the treatment of adult patients with previously treated follicular lymphoma. [Celgene Corporation] Press Release

Bluebird Bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

Bluebird Bio, Inc. and Forty Seven, Inc. announced that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 plus magrolimab, with Bluebird’s ex vivo lentiviral vector hematopoietic stem cell gene therapy platform. [Bluebird Bio, Inc.] Press Release

NEW Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies
January 9-12, 2020
San Diego, California, United States

Visit our events page to see a complete list of events in the community.

NEW Research Fellow – Iron-Altered Hematopoiesis (New York Blood Center)

Scientist – Hematopoietic Stem and Progenitor Cell Biology (STEMCELL Technologies Inc.)

Doctoral Student Position – Immunology and Gene Therapy (Karolinska Institutet)

Postdoctoral Fellow – Erythropoiesis (Mount Sinai School of Medicine)

PhD Studentships – Molecular and Cell Biology (University of Oxford)

Faculty Position – Stem Cell Biology and Regenerative Medicine (Yale University School of Medicine)

Postdoctoral Position – Immune-Targeting of Leukemic Stem Cells (Karolinska Institutet)

Research Assistant – Stem Cells and Engineering (New York Blood Center)

Group Leader – Vascular Biology, Hematopoiesis or Cardiovascular Disease (University of Wurzburg)

Postdoctoral Fellow – Normal and Malignant Hematopoiesis (Versiti Blood Research Institute)

PhD Positions – Cancer and Developmental Biology (Peter MacCallum Cancer Centre)

Research Fellow – Iron-Altered Hematopoiesis (New York Blood Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.